SEC Form 4 · accession 0001179110-17-014822
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Dec 1, 2017
Accepted (ET)
Dec 4, 2017 · 3:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2017 | M | 26,178 | $3.06 | A | 150,579 | D | |
| Common StockF1 | Dec 1, 2017 | S | 18,194 | $5.0318 | D | 132,385 | D | |
| Common StockF2 | Dec 1, 2017 | S | 5,037 | $5.0495 | D | 127,348 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.06 | Dec 1, 2017 | M | 26,178 | D | — | Feb 12, 2018 | Common Stock | 26,178 | 0 | D |
Explanation of responses
- F1Represents the sale of 18,194 shares in multiple transactions, ranging in price from $5.0000 to $5.1100, resulting in a weighted-average sale price per share of $5.0318. The reporting person will provide, upon request by SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
- F2Represents the sale of 5,037 shares in multiple transactions, ranging in price from $5.0000 to $5.1100, resulting in a weighted-average sale price per share of $5.0495. The reporting person will provide, upon request by SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range.
- F3The option is fully vested and immediately exercisable.